Special Issues

Special Issue Title: Obesity in pregnancy: risks and management

· Print Special Issue Flyer

· Deadline for manuscript submissions: 28 February 2021

Special Issue Editor

Guest Editor

M.D. Prof. Gideon Koren

Adelson faculty of medicine, Ariel University, and Motherisk Israel Program, Shamir Hospital, Israel

Website | E-Mail

Interests: Clinical pharmacology During Development, Drugs in Pregnancy

Special Issue Information

Dear Colleagues,

Obesity in pregnancy is associated with serious adverse maternal and fetal effects, including infertility, gestational diabetes, preeclampsia, intrauterine fetal and neonatal death, neural tube defects and many other. Because the prevalence of obesity in pregnancy has been steadily increased over the last few decades, its health impacts are much more serious. According to the World Health Organization, It has been estimated that overweight and obesity affect over 50 million women globally in upper and middle income countries. In the United States, a third of the women are obese and the yearly number of obese pregnant women exceeds 1 million.

Obesity-related hyperinsulinemia and subsequent hyperandrogenemia increase the risk of anovulatory cycles and the chance of conception decreases. Obesity is associated with increased risk of caesarian section, premature placental abruption, perineal tear, puerperal fever, severe puerperal infections, would healing complications, complications of obstetric anesthesia, postpartum hemorrhage, sepsis, obstetric shock, ICU admission and combined severe maternal morbidity and mortality. Maternal obesity is associated with long term overweight retention and its attendant long term morbidity with diabetes mellitus and cardiovascular risks. Maternal overweight and obesity are associated with increased risks for congenital malformations such as neural tube defects, cardiovascular risks, hydrocephaly, oral cleft and limb reduction anomalies.

In this special issue, leading scientists will be addressing emerging knowledge related to important challenges in evaluating, preventing and managing obesity in pregnancy, with focus on short and long term maternal risks, child risks, congenital malformations and pharmacological and non- pharmacological management.

M.D. Prof. Gideon Koren

Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at https://ceog.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Clinical and Experimental Obstetrics & Gynecology is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1250. We normally offer a discount about 30% (APC: $850) to all contributors invited by the Editor-in-Chief, Guest Editor (GE) and Editorial board member. Submitted papers should be well formatted and use good English.

Keywords

Obesity, Overweight, Pregnancy, Maternal risks, Fetal risks, Long term risks

Share This Special Issue

Planned Papers

Title: Maternal high fat diet and fetal programming of obesity
Author: Seray Kabaran

Title: Analysis of selected diet components
Author: Grazyna Jarząk-Bielecka

Title: Patient with Martin-Bell syndrome and premenstrual syndrome, tendency to obesity from puberty
Author: Grazyna Jarząk-Bielecka

Published papers

Please wait a minute...

For Selected:

Download Citations
EndNote Reference Manager ProCite BibTeX RefWorks

Toggle Thumbnails

Select

Obesity, neural tube defects and folic acid—A complex relationship

Gideon Koren, Yusuf C Kaplan

Clinical and Experimental Obstetrics & Gynecology 2021, 48 (2): 223-227. DOI: 10.31083/j.ceog.2021.02.2304

Abstract （22）

PDF（pc）（178KB）（4）

Save

Obesity is associated with twofold increased risk of neural tube defects (NTD). Research has repeatedly shown that about 70% of NTD are folic-acid dependent. Yet, there is controversy whether folic acid status is the main determinant of the increased risk of obesity-induced NTD. The rational for this review is to update and discuss the evidence on the link between obesity, folic acid and NTD, in an attempt to shed light on the question whether optimal folic acid dose schedule can mitigate this risk. During pregnancy maternal folate requirements increase by 5–10-fold, as folate is diverted towards the placenta and fetus, as well as supporting different maternal organs. Correspondingly, low maternal folate status has been associated with birth defects in fetal anatomical regions particularly sensitive to reduced folate intake including oral cleft, cardiovascular defects and NTD. A recent study has documented decreased placental folate transporter expression and activity in the first and second trimesters among obese mothers. This may explain the higher incidence on NTD in infants of obese women, as less folate may find its way to the developing fetus during the sensitive periods for creating NTD. Recent pharmacokinetic results indicate that steady state levels of folate are almost perfectly defined by the dose per lean body weight (LBW). The mean dose per kg LBW that would be expected to result in steady state serum folate level of > 15.9 nmol/L was identified as 0.0073 mg/kg LBW. A large study found no differences in dietary supplementations of folic acid, yet obese women exhibited lower median serum folate as well as lower mean serum B12 levels, but no differences in mean RBC folate levels. There was a negative correlation between increasing BMI and both serum folate and plasma B12. Future research will be needed to incorporate more fully, in addition to evidence of NTD, obesity and folic acid intake, also direct measurements of serum and RBC folate, as well as other confounders, in order to create a model that will shed light on these complex interactions.